Mometasone: Uses, Dosage & Side Effects

What Is Mometasone and What Is It Used For?

Mometasone furoate is a potent synthetic glucocorticosteroid that was first approved for clinical use in the late 1980s and has since become one of the most widely prescribed corticosteroids worldwide. Its chemical structure—a chlorinated derivative of beclomethasone—confers exceptionally high affinity for the intracellular glucocorticoid receptor, resulting in potent anti-inflammatory activity at the site of application. Mometasone is classified as a Group III (potent) topical corticosteroid in the European four-tier classification system, placing it in the same potency category as betamethasone valerate 0.1% and fluocinolone acetonide 0.025%. This potency classification is crucial for clinical decision-making, as it determines the suitability of the medication for different body areas, patient populations, and treatment durations.

The mechanism of action of mometasone furoate is shared with other glucocorticosteroids. After penetrating the cell membrane, mometasone binds to cytoplasmic glucocorticoid receptors, forming an activated receptor-steroid complex. This complex translocates to the cell nucleus, where it binds to specific DNA sequences known as glucocorticoid response elements (GREs). This binding modulates the transcription of numerous target genes, resulting in the upregulation of anti-inflammatory proteins (such as lipocortin-1, which inhibits phospholipase A2) and the downregulation of pro-inflammatory mediators including interleukins (IL-1, IL-2, IL-6), tumor necrosis factor-alpha (TNF-α), and various chemokines. The net effect is a suppression of the inflammatory cascade at multiple levels: reduced capillary permeability and vasodilation, inhibition of leukocyte migration and accumulation at inflammatory sites, decreased production of inflammatory prostaglandins and leukotrienes, and stabilization of lysosomal membranes. Additionally, mometasone exerts a direct antipruritic effect by reducing the release of histamine and other itch mediators from mast cells.

A key pharmacological advantage of mometasone furoate is its very low systemic bioavailability. When applied topically to intact skin, less than 0.7% of the applied dose is absorbed into the systemic circulation. For the nasal spray formulation, systemic bioavailability is remarkably low at less than 0.1% of the administered dose. This low systemic absorption is attributable to the furoate ester modification, which is rapidly metabolized upon entry into the systemic circulation. This pharmacokinetic property allows mometasone to deliver potent local anti-inflammatory effects while significantly reducing the risk of systemic corticosteroid side effects such as adrenal suppression, osteoporosis, and metabolic disturbances—a critical advantage for long-term or widespread topical use.

Topical Mometasone (Skin Conditions)

Topical mometasone furoate 0.1% is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and children. The primary indications include atopic dermatitis (eczema), psoriasis, contact dermatitis, seborrheic dermatitis, and other inflammatory skin conditions. The cream formulation is suitable for moist, non-dry, or weeping skin conditions, as well as for application to areas where a non-greasy formulation is preferred. The ointment formulation, with its occlusive, greasy base, is recommended for dry, thickened, and scaly skin lesions, as it provides enhanced moisturization and improves drug penetration into the stratum corneum. The cutaneous solution is primarily designed for use on the scalp and other hairy areas, but can also be applied to other body sites and is particularly suitable for weeping or exudative skin conditions.

Clinical trials and systematic reviews have demonstrated that mometasone furoate 0.1% applied once daily is as effective as many other potent topical corticosteroids applied twice daily, offering a convenience advantage that may improve treatment adherence. The British Association of Dermatologists (BAD) guidelines and the European Academy of Dermatology and Venereology (EADV) recommendations both support the use of potent topical corticosteroids like mometasone as first-line therapy for moderate-to-severe inflammatory skin conditions, with the caveat that treatment should be for the shortest duration necessary and that emollients should be used as adjunctive therapy.

Nasal Mometasone (Allergic Rhinitis and Nasal Polyps)

Mometasone furoate nasal spray (50 mcg per spray, typically administered as two sprays per nostril once daily for a total dose of 200 mcg) is one of the most widely prescribed intranasal corticosteroids globally. It is approved for the treatment of seasonal and perennial allergic rhinitis in adults and children aged 3 years and older, as well as for the treatment of nasal polyps in adults. The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines recommend intranasal corticosteroids as the single most effective pharmacotherapy for moderate-to-severe allergic rhinitis, as they effectively control all four cardinal nasal symptoms: congestion, sneezing, rhinorrhea, and nasal itching. Mometasone nasal spray typically begins to show therapeutic effect within 12 hours of the first dose, with maximal benefit achieved after approximately two weeks of regular use.

Inhaled Mometasone (Asthma)

Mometasone furoate inhalation powder (Asmanex Twisthaler) is approved as a maintenance treatment for asthma in adults and children aged 12 years and older. Available in 200 mcg and 400 mcg doses, inhaled mometasone is classified as a controller medication that reduces airway inflammation, decreases the frequency and severity of asthma exacerbations, and improves lung function. The Global Initiative for Asthma (GINA) 2024 guidelines recommend inhaled corticosteroids, including mometasone, as the cornerstone of controller therapy for persistent asthma. Like other inhaled corticosteroids, mometasone is not a rescue medication and should not be used to treat acute bronchospasm. Patients should be advised to rinse their mouth with water and spit out after each inhalation to reduce the risk of oropharyngeal candidiasis.

What Should You Know Before Using Mometasone?

Contraindications

Mometasone furoate must not be used in patients with a known hypersensitivity (allergy) to mometasone furoate, other corticosteroids, or any of the excipients present in the specific formulation. The following conditions are contraindications for topical mometasone:

• Untreated skin infections: Topical corticosteroids can mask the signs of infection and allow bacteria, fungi, or viruses to proliferate. Do not apply mometasone to infected skin unless the infection is being treated concurrently with an appropriate antimicrobial agent.
• Rosacea (facial redness): Topical corticosteroids can significantly worsen rosacea and are contraindicated in this condition.
• Acne vulgaris: Corticosteroids can exacerbate acne and are not appropriate treatments for acne.
• Perioral dermatitis: A condition characterized by papules and pustules around the mouth that is worsened by topical corticosteroids.
• Viral skin infections: Including herpes simplex (cold sores), varicella (chickenpox), herpes zoster (shingles), and molluscum contagiosum. Corticosteroids suppress local immune responses and can allow viral infections to spread.
• Fungal skin infections: Such as tinea pedis (athlete's foot), tinea corporis (ringworm), and candidal infections. These require specific antifungal treatment.
• Parasitic skin infections: Such as scabies, which requires specific antiparasitic treatment.
• Open wounds and damaged skin: Including ulcers and post-vaccination skin reactions. Absorption is dramatically increased through damaged skin.
• Diaper dermatitis in infants: The occlusive effect of diapers greatly increases corticosteroid absorption.

Warnings and Precautions

Topical corticosteroids, including mometasone, can mask, activate, or exacerbate skin infections. If a skin infection develops during treatment, appropriate antimicrobial therapy should be initiated. If the infection does not respond promptly, mometasone should be discontinued until the infection is adequately controlled.

Occlusive dressings (bandages that cover the treated area) should be avoided when treating infected eczema and when treating children, as they increase corticosteroid absorption and the risk of systemic effects. As with all potent topical corticosteroids, abrupt discontinuation after prolonged treatment should be avoided. When long-term treatment is discontinued, the dose should be tapered gradually—for example, by reducing the frequency of application from daily to every other day, then to twice weekly, before stopping entirely. This prevents rebound dermatitis, characterized by intense redness, burning, and stinging.

Avoid getting mometasone in the eyes. Contact your doctor immediately if you experience blurred vision or other visual disturbances during treatment, as these may indicate rare but serious ocular complications such as glaucoma or central serous chorioretinopathy.

Pregnancy and Breastfeeding

The safety of mometasone furoate during pregnancy has not been established in adequate and well-controlled studies in humans. Animal reproduction studies with corticosteroids have demonstrated teratogenic effects (abnormalities in the developing fetus) including cleft palate and intrauterine growth restriction. While topical corticosteroids have not been conclusively shown to cause birth defects in humans, the potential risk cannot be excluded. Mometasone should only be used during pregnancy if the expected benefit to the mother justifies the potential risk to the fetus, and only under the direct supervision of a healthcare provider. If used during pregnancy, it should be applied to the smallest area possible for the shortest duration necessary.

It is not known whether topical mometasone furoate is excreted in human breast milk. Given that other corticosteroids are detectable in breast milk, caution is warranted. Mometasone should not be applied to the breasts immediately before nursing. The decision to use mometasone during breastfeeding should be made in consultation with a healthcare provider, weighing the benefit of treatment against the potential risk to the infant.

How Does Mometasone Interact with Other Drugs?

Because topical mometasone furoate has extremely low systemic bioavailability (less than 0.7% of the applied dose reaches the bloodstream), clinically significant drug interactions with topical formulations are very rare. The drug is primarily metabolized locally in the skin and, upon entering the systemic circulation, is rapidly cleared by hepatic metabolism via the cytochrome P450 3A4 (CYP3A4) enzyme system. However, for nasal and inhaled formulations, where systemic absorption—though still low—may be somewhat greater over prolonged use, certain drug interactions merit clinical attention.

Major Interactions

The most clinically significant interactions involve strong inhibitors of the CYP3A4 enzyme, which is the primary pathway for mometasone metabolism. Co-administration of these inhibitors with inhaled or nasal mometasone can reduce the metabolic clearance of mometasone, leading to increased systemic corticosteroid levels and a heightened risk of adrenal suppression and other systemic side effects.

Minor Interactions

Moderate CYP3A4 inhibitors may produce a smaller but clinically relevant increase in systemic mometasone levels, particularly with prolonged use of nasal or inhaled formulations. These interactions are generally less concerning than those with strong CYP3A4 inhibitors but still warrant medical awareness.

What Is the Correct Dosage of Mometasone?

Adults

Children

Elderly

No specific dose adjustment is required for elderly patients. However, elderly skin is generally thinner and more fragile, which may increase susceptibility to topical corticosteroid side effects such as skin atrophy and purpura. Treatment should be supervised by a healthcare provider, and the smallest effective amount should be used for the shortest necessary duration. Regular skin assessments are recommended during prolonged treatment.

Missed Dose

If you miss a dose of mometasone, apply it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not apply a double dose to make up for the missed application. For topical formulations, inconsistent use may reduce therapeutic efficacy; try to apply your medication at the same time each day to establish a consistent routine.

Overdose

Chronic overuse of topical corticosteroids can lead to irreversible skin changes including severe skin thinning (atrophy), striae (stretch marks), telangiectasia (visible blood vessels), and steroid-dependent dermatitis. If HPA axis suppression is suspected, the drug should be gradually withdrawn under medical supervision, and the patient may require supportive measures including systemic corticosteroid supplementation during physiological stress periods.

What Are the Side Effects of Mometasone?

Like all corticosteroids, mometasone furoate can cause side effects, although not everyone will experience them. The frequency and severity of side effects depend on the formulation used, the body area treated, the duration of treatment, and whether occlusive dressings are employed. Side effects are generally more common with prolonged use, application to large body surface areas, use under occlusion, and application to thin-skinned areas such as the face, eyelids, groin, and axillae.

Topical Mometasone Side Effects

Nasal Spray Side Effects

Inhaled Mometasone Side Effects

How Should You Store Mometasone?

Proper storage of mometasone ensures that the medication retains its potency and remains safe for use throughout its shelf life. Mometasone furoate formulations should be stored at temperatures not exceeding 25°C (77°F) in their original packaging. Protect the medication from direct sunlight, excessive heat, and freezing. The cream and ointment tubes should be kept tightly closed when not in use to prevent contamination and drying out. The nasal spray should be stored upright and primed before first use according to the manufacturer's instructions. The Asmanex Twisthaler should be stored in a dry place with the cap tightly closed to protect the powder from moisture.

Keep all medications out of the sight and reach of children. Do not use mometasone after the expiration date printed on the packaging. The expiration date refers to the last day of the stated month. Do not dispose of medications via wastewater or household waste. Return unused or expired medications to a pharmacy for appropriate disposal. These measures help protect the environment from pharmaceutical contamination.

What Does Mometasone Contain?

Active Ingredient

The active ingredient in all mometasone formulations is mometasone furoate. The concentration varies by formulation: topical cream and ointment contain 0.1% (1 mg/g) mometasone furoate; the nasal spray delivers 50 mcg per actuation; and the inhalation powder is available in 200 mcg and 400 mcg doses.

Inactive Ingredients by Formulation

Available Pack Sizes

Mometasone cream and ointment are typically available in tubes containing 30 g or 100 g. The cutaneous solution is available in plastic bottles containing 30 ml, 100 ml, or 250 ml. The nasal spray is supplied in metered-dose pump bottles containing 60 or 140 sprays. The Asmanex Twisthaler (inhalation powder) contains 30, 60, or 120 inhalations. Not all pack sizes may be marketed in every country.